Literature DB >> 25003863

Military HIV policy assessment in sub-Saharan Africa.

Anne Goldzier Thomas1, Michael P Grillo1, Djeneba Audrey Djibo1, Braden Hale1, Richard A Shaffer1.   

Abstract

While HIV/AIDS continues to inflict a heavy toll on African militaries, the military commitment and leadership response has been inconsistent, as reflected by variable presence of a written HIV policy. The Department of Defense HIV/AIDS Prevention Program collaborates with most sub-Saharan military HIV/AIDS programs. In 2010, 28 invited countries (80%) completed a self-administered survey describing their program, including policy. Descriptive and nonparametric measures were calculated. The majority (57%) of respondents reported having a written military HIV policy. Of these, 86% included HIV testing, 88% required recruit testing, and 96% denied entry for those testing HIV-positive. Mandatory HIV testing was reported by 71%, occurring before deployments, peacekeeping missions, foreign training, and when clinically indicated. Southern African militaries were most likely to require HIV testing. The majority of militaries allowed deployment of HIV-positive personnel in-country, whereas few allowed foreign deployment. Most sub-Saharan militaries screen applicants for HIV and other diseases to determine duty fitness, resulting in near universal HIV negative recruit cohorts. No militaries discharge personnel from service if they acquire HIV. Legal challenges to military HIV policies may hinder finalization and dissemination of policies. Lack of HIV policies impedes routine testing and earlier care and treatment for HIV-infected personnel. Reprint &
Copyright © 2014 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Year:  2014        PMID: 25003863     DOI: 10.7205/MILMED-D-13-00495

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  1 in total

1.  The Missing Men: HIV Treatment Scale-Up and Life Expectancy in Sub-Saharan Africa.

Authors:  Alexander C Tsai; Mark J Siedner
Journal:  PLoS Med       Date:  2015-11-24       Impact factor: 11.069

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.